Novartis to Resolve Texas, U.S. Eczema Drug Probe
This article is for subscribers only.
Novartis AG agreed to pay $19.9 million to the U.S. and Texas in settlement of claims that it unlawfully marketed Elidel, a topical cream used to treat eczema.
“Evidence uncovered by the state revealed that Novartis improperly urged physicians to prescribe Elidel to children under two years of age for purposes that had not been approved by the U.S. Food and Drug Administration,” Texas Attorney General Greg Abbott said today in a statement.